Home / Health / Breakthrough Male Birth Control Pill Moves to Human Trials
Breakthrough Male Birth Control Pill Moves to Human Trials
23 Oct
Summary
- Experimental drug temporarily stops sperm motility for 6-8 hours.
- New male contraceptive pill targets enzyme essential for sperm swimming.
- Researchers hope to begin human trials within two years.
An experimental male contraceptive pill is advancing toward human trials following a significant multimillion dollar grant. Researchers at Weill Cornell Medicine are developing a drug that can temporarily inhibit sperm motility for a 6-8 hour period. This innovative approach targets a specific enzyme, soluble adenylyl cyclase (sAC), crucial for sperm's ability to swim and mature.
Unlike existing methods that focus on sperm production, this pill acts on ejaculated sperm, disabling their motility shortly after administration. The effect is designed to be rapid, brief, and fully reversible as drug levels decrease. This offers a novel, on-demand contraceptive solution, potentially easing the burden of birth control currently placed primarily on women.
Initial animal studies have shown no side effects, even at high doses, though human testing is required to confirm safety. Experts anticipate initiating human trials within the next two years, but emphasize that widespread availability will take several more years of rigorous testing. The development represents a significant step towards shared responsibility in contraception.
